Literature DB >> 16216394

DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation.

Shigeto Yoshida1, Takao Tanaka, Yoko Kita, Sachiko Kuwayama, Noriko Kanamaru, Yumiko Muraki, Satomi Hashimoto, Yoshikazu Inoue, Mitsunori Sakatani, Eiji Kobayashi, Yasufumi Kaneda, Masaji Okada.   

Abstract

We investigated the immunogenicity and protective efficacy of DNA vaccine combinations expressing mycobacterial heat shock protein 65 (Hsp65) and interleukin-12 (IL-12) using gene gun bombardment and the hemagglutinating virus of Japan (HVJ)-liposome method. A mouse IL-12 expression vector (mIL-12 DNA) encoding single-chain IL-12 proteins comprised of p40 and p35 subunits were constructed. In a mouse model, a single gene gun vaccination with the combination of Hsp65 DNA and mIL-12 DNA provided a remarkably high degree of protection against challenge with virulent Mycobacterium tuberculosis; bacterial numbers were 100-fold lower in the lungs compared to BCG-vaccinated mice. To explore the clinical use of the DNA vaccines, we evaluated HVJ-liposome encapsulated Hsp65 DNA and mIL-12DNA (Hsp65 + mIL-12/HVJ). The HVJ-liposome method improved the protective efficacy of the Hsp65 DNA vaccine compared to gene gun vaccination. Hsp65 + mIL-12/HVJ induced CD8+ cytotoxic T lymphocyte activity against Hsp65 antigen. Most importantly, Hsp65+mIL-12/HVJ vaccination resulted in a greater degree of protection than that evoked by BCG. This protective efficacy was associated with the emergence of IFN-gamma-secreting T cells and activation of proliferative T cells and cytokines (IFN-gamma and IL-2) production upon stimulation with Hsp65 and antigens from M. tuberculosis. These results suggest that Hsp65 + IL-12/HVJ could be a promising candidate for a new tuberculosis DNA vaccine, which is superior to BCG vaccine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16216394     DOI: 10.1016/j.vaccine.2005.08.103

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  Utilizing IL-12, IL-15 and IL-7 as Mucosal Vaccine Adjuvants.

Authors:  Liljana Stevceva; Marcin Moniuszko; Maria Grazia Ferrari
Journal:  Lett Drug Des Discov       Date:  2006       Impact factor: 1.150

Review 2.  Interleukin-12 and tuberculosis: an old story revisited.

Authors:  Andrea M Cooper; Alejandra Solache; Shabaana A Khader
Journal:  Curr Opin Immunol       Date:  2007-08-16       Impact factor: 7.486

3.  A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague.

Authors:  Hitoki Yamanaka; Teri Hoyt; Xinghong Yang; Sarah Golden; Catharine M Bosio; Kathryn Crist; Todd Becker; Massimo Maddaloni; David W Pascual
Journal:  Infect Immun       Date:  2008-08-11       Impact factor: 3.441

4.  The study of novel DNA vaccines against tuberculosis: induction of pathogen-specific CTL in the mouse and monkey models of tuberculosis.

Authors:  Masaji Okada; Yoko Kita; Toshihiro Nakajima; Satomi Hashimoto; Hitoshi Nakatani; Shiho Nishimatsu; Yasuko Nishida; Noriko Kanamaru; Yasuhumi Kaneda; Yasushi Takamori; David McMurray; Esterlina V Tan; Marjorie L Cang; Paul Saunderson; E C Dela Cruz
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

5.  Immunostimulatory activity of major membrane protein II from Mycobacterium tuberculosis.

Authors:  Yumiko Tsukamoto; Masumi Endoh; Tetsu Mukai; Yumi Maeda; Toshiki Tamura; Masanori Kai; Masahiko Makino
Journal:  Clin Vaccine Immunol       Date:  2010-12-15

6.  Anti-IL-6 receptor antibody causes less promotion of tuberculosis infection than anti-TNF-α antibody in mice.

Authors:  Masaji Okada; Yoko Kita; Noriko Kanamaru; Satomi Hashimoto; Yasushi Uchiyama; Masahiko Mihara; Yoshikazu Inoue; Yoshiyuki Ohsugi; Tadamitsu Kishimoto; Mitsunori Sakatani
Journal:  Clin Dev Immunol       Date:  2011-02-22

7.  An IL-12 DNA vaccine co-expressing Yersinia pestis antigens protects against pneumonic plague.

Authors:  Hitoki Yamanaka; Teri Hoyt; Richard Bowen; Xinghong Yang; Kathryn Crist; Sarah Golden; Massimo Maddaloni; David W Pascual
Journal:  Vaccine       Date:  2008-10-26       Impact factor: 3.641

8.  Preclinical study and clinical trial of a novel therapeutic vaccine against multi-drug resistant tuberculosis.

Authors:  Masaji Okada; Yoko Kita; Satomi Hashimoto; Hitoshi Nakatani; Shiho Nishimastu; Yumiko Kioka; Yasuko Takami
Journal:  Hum Vaccin Immunother       Date:  2016-12-14       Impact factor: 3.452

9.  Novel therapeutic vaccines [(HSP65 + IL-12)DNA-, granulysin- and Ksp37-vaccine] against tuberculosis and synergistic effects in the combination with chemotherapy.

Authors:  Yoko Kita; Satomi Hashimoto; Toshihiro Nakajima; Hitoshi Nakatani; Shiho Nishimatsu; Yasuko Nishida; Noriko Kanamaru; Yasuhumi Kaneda; Yasushi Takamori; David McMurray; Esterlina V Tan; Marjorie L Cang; Paul Saunderson; E C Dela Cruz; Masaji Okada
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

10.  Adjunctive immunotherapy with α-crystallin based DNA vaccination reduces Tuberculosis chemotherapy period in chronically infected mice.

Authors:  Priyanka Chauhan; Ruchi Jain; Bappaditya Dey; Anil K Tyagi
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.